NY-PERMUTIVE
2.11.2021 09:17:08 CET | Business Wire | Press release
Permutive , an audience platform for publishers and advertisers, which enables media to be traded in a privacy-safe way, has secured $75M in Series C from SoftBank Vision Fund 2. It brings Permutive’s total raised to date to $105M, with previous investors EQT Ventures, Octopus Ventures, and ACE & Company also participating. The funding will enable Permutive to grow its patented on-device technology and scale its Audience Platform to create a global privacy-first infrastructure for programmatic advertising, now a $155B industry.
Personal data has powered digital advertising for over ten years; its misuse has captured the attention of regulators and consumers. This reckoning has triggered a seismic power shift from adtech owned programmatic advertising to a publisher owned privacy-first web. Via Permutive's Audience Platform, which has seen a 20x growth in targeted ads in the last two years, publishers can deliver a personalized advertising experience without compromising privacy via consented first-party data. The company has built a client roster comprising some of the most highly regarded publishers in Europe and North America, including News Corp, Hearst, BuzzFeed, Penske, Future plc, The Guardian, Vox Media, Insider, Hubert Burda Media and Condé Nast International.
“Publishers are the foundation of the web, and the relationship they have with their users is the backbone of digital advertising,” says Joe Root, CEO and co-founder, Permutive . “As privacy shifts the economics of the internet towards this publisher-owned web, a privacy-first infrastructure will ensure this next iteration of digital advertising is immune to privacy chaos, will scale, and thrive.”
Advertisers are buying directly from publishers because they are a stable foundation for data-driven advertising and are trusted partners when navigating the impact of browser changes and tightening privacy regulations. But without an infrastructure to support this transition to a publisher-owned privacy-first web, the industry won't achieve scale. Permutive has created a new model for digital advertising with privacy at its core, where publishers and advertisers can own and control their data while planning and buying campaigns. This brings transparency, scale and privacy to programmatic advertising for the first time.
“To underpin a privacy-first web requires unique technology. As a leader in on-device technology, Permutive can bring a complicated landscape that’s being significantly disrupted into a privacy-safe future. The company’s technology is now running on over 1 billion devices a month globally, and we see tremendous opportunity for sustained growth as on-device processing reshapes adtech,” says Max Ohrstrand, investor for SoftBank Investment Advisers .
Permutive’s funding comes at a critical time for the digital advertising industry. Creating a privacy-first infrastructure built to protect user privacy instils trust, transparency, and efficiency in programmatic ad spending.
-ENDS-
Notes to editor:
About Permutive
Permutive is rebuilding data in programmatic advertising to protect privacy. As the only Audience Platform built on patented on-device and privacy-preserving technology, we enable premium advertisers and publishers to plan, build and activate cohorts — all while keeping everyone’s data safe.
Working with clients across Europe and North America, publishers using Permutive include News Corp, Hearst, BuzzFeed, Penske Media, Future plc, The Guardian, Vox Media, Insider, Hubert Burda Media and Condé Nast International.
Find out more at permutive.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
